ClinicalTrials.gov
public full text
Public Domain
Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial
The purpose of this study is to evaluate whether the newly-approved everolimus-eluting stent is not inferior to the sirolimus-eluting stent in terms of the rate of target-lesion revascularization at 1-year and death or myocardial infarction at 3-year after stent implantation in the real world clinical practice.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Randomized Trial Comparing Two Sirolimus-Eluting Stents in Diabetes Mellitus#1096187
- Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE#980409
- Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers#913171
- The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study.#839021
- Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)#1007257
Record · ID 813811
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive